financetom
Business
financetom
/
Business
/
AI, cloud funding in US, Europe and Israel to hit $79 bln in 2024, Accel says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AI, cloud funding in US, Europe and Israel to hit $79 bln in 2024, Accel says
Oct 17, 2024 1:19 PM

By Supantha Mukherjee

STOCKHOLM, Oct 16 (Reuters) - Funding of artificial

intelligence and cloud companies in the U.S., Europe and Israel

is rising after three years of decline and is estimated to hit

$79.2 billion by the end of the year, venture capital firm Accel

said in a report on Wednesday.

That is a 27% increase over 2023's $62.5 billion, and

investments involving generative AI companies represent about

40% of the 2024 figure.

"The tectonic shift we are seeing with AI right now is

bigger than anything that we have seen in the past, be it

broadband or mobile or cloud," Philippe Botteri, a partner at

Accel, said in an interview.

Of the $56 billion invested in generative AI in 2023 and

2024 combined, about 80% has gone into U.S. companies versus 20%

for Europe and Israel. Two-thirds of the AI funding, or $37

billion, has been invested into companies building foundation

models, Accel said.

Microsoft ( MSFT )-backed OpenAI raised $6.6 billion earlier this

month, Elon Musk's xAI raised $6 billion in May, and Anthropic

received $4 billion from Amazon ( AMZN ).

While OpenAI, Anthropic, and xAI led the funding rounds in

the U.S., Mistral, Aleph Alpha and DeepL got the most funding in

Europe.

About $25 billion was invested in private GenAI companies in

the U.S. this year versus $6.4 billion in Europe, Botteri said.

However, funding in Europe is growing at a faster rate, as

in 2023, generative AI investment in Europe was just $2.4

billion, a fraction of the $22.4 billion in the U.S.

Beyond AI, the outlook is not as bright, and the era of high

software growth has been replaced by a focus on profitability,

Accel said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amazon Web Services, Saudi's Humain Expand Partnership to Further AI Innovation
Amazon Web Services, Saudi's Humain Expand Partnership to Further AI Innovation
Nov 19, 2025
02:23 PM EST, 11/19/2025 (MT Newswires) -- Amazon Web Services, Amazon's ( AMZN ) cloud computing platform, and Saudi Arabian artificial intelligence company Humain plan to deploy and manage up to 150,000 AI accelerators at a data center facility in Riyadh, the companies said Wednesday. The data center infrastructure will use the Nvidia (NVDA) GB300 AI infrastructure and AWS's Trainium...
BRIEF-Kitron To Buy 100% Of DeltaNordic Shares
BRIEF-Kitron To Buy 100% Of DeltaNordic Shares
Nov 19, 2025
Nov 19 (Reuters) - Kitron ASA: * KITRON ACQUIRES DELTANORDIC, STRENGTHENING ITS POSITION IN DEFENCE * KITRON ASA - TO BUY 100% OF DELTANORDIC SHARES * KITRON ASA - PURCHASE IS BASED ON AN ENTERPRISE VALUE OF SEK 1,255 MILLION (EUR 114 MILLION) ON A DEBT- AND CASH-FREE BASIS * KITRON ASA: KITRON OUTLOOK 2025 (EXCLUDING DELTANORDIC): REVENUE EUR 700-740...
--Marzetti Raises Quarterly Dividend to $1.00 a Share; Payable Dec. 31 to Holders of Record Dec. 5
--Marzetti Raises Quarterly Dividend to $1.00 a Share; Payable Dec. 31 to Holders of Record Dec. 5
Nov 19, 2025
02:22 PM EST, 11/19/2025 (MT Newswires) -- Price: 170.35, Change: +0.13, Percent Change: +0.08 ...
Johnson & Johnson's Janssen Gets FDA Approval for Darzalex in Amyloidosis
Johnson & Johnson's Janssen Gets FDA Approval for Darzalex in Amyloidosis
Nov 19, 2025
02:21 PM EST, 11/19/2025 (MT Newswires) -- Johnson & Johnson's ( JNJ ) Janssen Biotech unit has been granted traditional approval to Darzalex Faspro with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain amyloidosis, the US Food and Drug Administration said Wednesday. The approval for Darzalex, with active ingredients daratumumab and hyaluronidase-fihj, was based on major organ deterioration progression...
Copyright 2023-2026 - www.financetom.com All Rights Reserved